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Effect of Prolactin-Induced Protein on Human Skin:
New Insight into the Digestive Action of This Aspartic
Peptidase on the Stratum Corneum and Its Induction
of Keratinocyte Proliferation
Shuji Sugiura1, Misao Tazuke2, Shoichi Ueno3, Yasuo Sugiura4, Ikuo Kato5, Yoshimitsu Miyahira6,
Yutaka Yamamoto3, Hiroshi Sato7, Jun Udagawa2, Masami Uehara8 and Hisashi Sugiura2,9
Human prolactin-induced protein (PIP) is a major protein found in exocrine fluids such as saliva and sweat.
Intriguingly, PIP possesses residues (human PIP (hPIP): PIP (29–63)) that display similarity to the aspartic peptidase
candidapepsin. Here, we aimed to determine the effect of PIP as a protease on normal skin structure. Using an
adhesive tape-stripping technique, we applied hPIP peptide on the corneocytes of normal-appearing facial skin
from infants with eczema and healthy infants and then analyzed the morphological structure of corneocytes with
Nile Red fluorescence. We also repeatedly applied the hPIP peptide onto the surface of a three-dimensional (3-D)
human skin model and then analyzed any changes to the stratum corneum and epidermis using light microscopy
and scanning electron microscopy. In both infant groups, a decrease in hydrophobic lipids from the cornified
envelope was observed after treatment with hPIP. The peptide hPIP appeared to digest the fine structure of the
stratum corneum and induce a proliferation of epidermal keratinocytes within the 3-D human skin model. Our
results suggest that aspartic peptidase of PIP found in sweat or saliva deteriorates the skin barrier in a de novo
manner, which potentially leads directly to the proliferation of epidermal keratinocytes without any external
antigenic factors.
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INTRODUCTION
Prolactin-induced protein (PIP) is a major protein found in
exocrine fluids such as saliva, sweat, tears, and breast milk
(Sa´nchez et al., 1992, Schenkels et al., 1995, Baechle et al.,
2006, Park et al., 2011, Raiszadeh et al., 2012). PIP consists of
a CD4-binding domain and residues essential for aspartic
peptidase activity (hPIP). The CD4 domain allows PIP to
specifically bind to T lymphocytes and inhibit their
programed cell death (Autiero et al., 1991, Gaubin et al.,
1999). Basmaciogullari et al. (2000) suggested that binding
between PIP and CD4 blocks the CD4–HLA-DR interaction.
Moreover, PIP has a local and systemic immunosuppressive
effect in mouse chronic allergic contact dermatitis (Sugiura
et al., 2010). However, the biological function of the aspartic
peptidase residues of human PIP has not been identified.
Intriguingly, the residues essential for the aspartic peptidase
activity of PIP are very similar to those of the fungal enzyme
candidapepsin (Caputo et al., 2000), which is known to
provoke skin damage similar to eczema (Bein et al., 2002).
We believe this similarity provides further justification for a
likely link between the protease activity of PIP and its
denaturing effect on normal human skin.
Patients with atopic dermatitis (AD) typically develop
lesions at flexor surfaces, particularly the antecubital and
popliteal fossae, as well as in the neck region. These sites
correspond to areas where sweat tends to accumulate.
Recently, the pruritogenic substance MGL_1304 was identi-
fied in sweat (Hiragun et al., 2013). This finding strongly
suggests that MGL_1304 causes an exacerbation of AD
because of a buildup of sweat on the skin. Moreover, we
also reasoned that the aspartic peptidase activity of PIP found
in sweat might be an exacerbation factor of AD. With regard
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to saliva, many babies with infantile eczema frequently show
exacerbation of this disorder in the perioral region where the
skin is in contact with saliva. Nonetheless, the exacerbation
factors within saliva for perioral infantile eczema have not
been identified.
These well-established observations concerning the effect of
saliva and sweat on the skin prompted us to clarify whether
the proteolytic activity of PIP found in these bodily fluids
might be responsible. Our results suggest that the aspartic
peptidase activity of PIP damages corneocytes, potentially
leading to the proliferation of epidermal keratinocytes.
RESULTS
In vivo localization and distribution of PIP on the skin
There was no clear difference in the staining appearance of
PIP–positive corneocytes between healthy individuals and
patients with AD. The number of PIP–positive corneocytes
and the intensity of staining of PIP varied from case to case
(Figure 1). Immunofluorescence analysis clearly detected PIP
at the eccrine ducts and upper surface of the stratum corneum,
with a weak signal at the middle and lower layer of the
stratum corneum in all six skin samples from AD patients
(Figure 1). Sequential tape-stripping analysis clarified that the
number of PIP–positive corneocytes decreased within three or
four layers in many of the healthy individuals (Figure 1).
However, numerous PIP–positive corneocytes were detected
in deeper layers in the stratum corneum of many AD patients
(Figure 1). The deepest layer with PIP–positive corneocytes
was 2, 2, 3, 4, 4, 6, and 6 in seven healthy individuals and 3,
4, 4, 8, 9, 9, 9, 9, and 9 in nine patients with AD. Vertical
distribution of PIP in layers of the stratum corneum of AD
patients showed that PIP was detected in significantly deeper
regions than in healthy individuals.
In vivo concentration of PIP in sweat and saliva
From dot-blot analysis of sweat, we determined the concen-
tration of PIP to be o0.4mg ml1 in two healthy individuals
and much higher than 10mg ml 1 in three healthy individuals.
Using the same technique, we found that the concentration of
PIP in sweat was o0.4mg ml1 in two patients and much
410mg ml1 in three patients with AD. The concentration of
PIP in saliva was determined to be 2–10mg ml1 in one infant
with eczema and very much 410mg ml1 in five infants with
eczema.
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Figure 1. In vivo localization and distribution of prolactin-induced protein (PIP) on the skin. In all cases examined, many corneocytes obtained by tape strippings
were positively stained with anti-PIP antibody, but the intensity of PIP staining and positive cell number varied from case to case (original magnification,  10).
Immunofluorescence studies show that PIP is clearly present at the eccrine ducts and upper surface of the stratum corneum. However, only a weak signal was
observed at the middle and lower layers of the stratum corneum. Immunolabeling of PIP with sequential tape strippings gave the strongest signal at the upper layer
of the stratum corneum, which diminished in the deeper layers. In deeper layers, immunolabeling of PIP was stronger in many atopic dermatitis (AD) patients than
in healthy individuals (HIs). Corneocytes were obtained from antecubital area (tape stripping from HIs and sequential tape stripping) or the upper arm (tape
stripping from AD). Bar in tape stripping¼ 250mm and in immunofluorescence and sequential tape stripping¼ 50mm.
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Morphological evaluation of the effect of hPIP on the
corneocytes of normal-appearing facial skin with toluidine blue
staining
Seven out of 10 samples from healthy infants showed more
obvious morphological deterioration of corneocytes in those
treated with hPIP (PIP (29–63)) (Figure 2) over samples treated
with control hPIP (chPIP D22S) or distilled water (DW)
(Figure 2). Morphological deterioration observed in these
experiments included partial loss or decline of toluidine blue
(TB) staining and partial loss or decline of a clear margin of
individual corneocytes. For 2 of the 10 samples, morphologi-
cal changes were almost equal among the three groups. One
of the 10 samples showed the most extensive morphological
changes in the DW applied group.
Thirteen out of 17 samples from infants with eczema
showed morphological deterioration of corneocytes most
clearly in those treated with hPIP (Figure 2) over those treated
with chPIP D22S or DW (Figure 2). For two of the 17 samples,
morphological changes were almost equal among the three
groups. One out of the 17 samples displayed morphological
changes that were more extensive in both the chPIP D22S and
hPIP applied groups than in the DW applied group. One of the
17 samples showed the most extensive morphological
changes in the DW applied group.
Application of DW itself provoked slight deterioration of
corneocytes in 4 out of the 10 samples from the healthy infant
group and in 11 out of the 17 of infants from the eczema
group. Loss or decline of TB staining tended to be more
profound in hPIP–treated corneocytes from infants in the
eczema group than from infants in the healthy group.
Decrease in hydrophobic lipid of cornified envelope from facial
corneocytes of infants treated with hPIP peptide assessed with
Nile Red staining
Hydrophobic lipids found on the cornified envelope (CE) are
stained by the fluorescent dye Nile Red (NR) (Greenspan et al.,
1985; Hirao et al., 2001). In both infants with eczema and
healthy infants, the density of NR-positive hydrophobic lipid
was decreased in corneocytes treated with hPIP peptide
compared with those treated with chPIP D22S or DW
(Figure 3a). The effect of hPIP, chPIP D22S, and DW on
corneocytes varied from case to case as shown in Figure 3b.
Decrease in hydrophobic lipids from the CE of facial corneo-
cytes of infants treated with hPIP was more significant
(Po0.05, the Student’s t-test) compared with those treated
with chPIP D22S (Figure 3c).
The digestive effect of hPIP peptide on the stratum corneum of a
human 3-D skin model observed by scanning electron
microscopy
Observations by scanning electron microscopy of over 1,000
or more high magnification images revealed the presence of
numerous openings on almost all keratinocytes that were
treated with hPIP peptide from 50 to 250mg ml1 (Figure 4).
Crucially, these openings were not observed on keratinocytes
treated with chPIP D22S (Figure 4).
The keratinocytes treated with hPIP also displayed many
small irregular-shaped holes in addition to the large rounded
holes (Figure 4). Moreover, aggregation of high-density mate-
rials was seen at the rim of these holes. Keratinocytes treated
with chPIP D22S display wave-like structures on their surfaces
but no holes were observed (Figure 4).
Inspection of the intercellular space between hPIP–treated
corneocytes showed that they were not tightly connected and
the peripheral edge of individual cells displayed fine wrinkles
with a lamellar appearance (Figure 4). By contrast, corneo-
cytes treated with chPIP D22S were tightly connected together
and the peripheral edge of individual cells showed no signs of
damage (Figure 4).
Proliferation of epidermal keratinocytes treated with hPIP within
a human 3-D skin model
The human three-dimensional (3-D) skin model treated with
hPIP peptide appeared to exfoliate and adopted a thick
lamellar appearance from the upper to the middle layers of
the stratum corneum (Figure 5a). By contrast, the skin model
treated with chPIP D22S peptide consistently maintained a
compact appearance (Figure 5a).
Model tissue samples treated with hPIP peptide at a
concentration of 25–250mg ml1 gave epidermal proliferation
of up to 5–6 cell layers compared with control cell layers of
up to 2–3 layers (Figure 5a). Mitotic epidermal cells and
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Figure 2. Morphological deterioration of facial corneocytes treated with
human prolactin-induced protein (hPIP) peptide assessed with toluidine blue
(TB). Morphological changes were more markedly induced in hPIP applied
corneocytes than in control hPIP (chPIP)– or distilled water (DW)–treated
corneocytes for both healthy infants and infants with eczema. The
morphological changes observed in our experiments included partial loss or
decline of TB staining and a partial loss or decline of the clear margin between
individual corneocytes. Bar¼ 50mm.
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Figure 3. Decrease in the hydrophobic lipid of cornified envelope from facial corneocytes treated with human prolactin-induced protein (hPIP) peptide as
evaluated by Nile Red (NR) staining. The corneocytes of normal-appearing facial skin from healthy infants and infants with eczema were stained with NR
(5mg ml1) fluorescent dye. (a) The corneocytes were treated with distilled water (DW), control hPIP (chPIP) D22S, or hPIP. (b) Distribution of chPIP/DW and hPIP/
DW. The columns in (c) show the mean±SD of chPIP/DW and hPIP/DW. The Student’s t-test was performed between chPIP/DW and hPIP/DW and an asterisk
indicates Po0.05. Bar in NR and phase contrast¼ 90mm and in merge¼ 30mm.
50 µg ml–1
hP
IP
ch
PI
P
100 µg ml–1 250 µg ml–1 100 µg ml–1 100 µg ml–1
1 µm2 µm8 µm8 µm
8 µm 8 µm 8 µm 2 µm 1 µm
8 µm
Figure 4. Digestive effect of human prolactin-induced protein (hPIP) peptide on the stratum corneum of a human three-dimensional (3-D) skin model observed
by scanning electron microscopy. Numerous openings are seen on the surface of keratinocytes of a human 3-D skin model treated with hPIP peptide.
Concentration of hPIP was as follows: 50, 100, or 250mg ml1. Original magnification of images is 2,500 or  10,000. Arrows highlight very small openings.
No openings are evident on the surface of keratinocytes in the human 3-D skin model treated with control hPIP (chPIP) peptide. Concentration of chPIP used to
treat the skin model was as follows: 50, 100, or 250mg ml1. Original magnification is 2,500 or 10,000.
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chromatin-rich nuclei (Figure 5c) were occasionally seen
after treatment with hPIP peptide at a concentration of
50–250mg ml1 (Figure 5a). Many epidermal cells were
positively stained with anti-proliferating cell nuclear antigen
antibody (Figure 5d).
When the concentration of hPIP peptide was increased
to 500mg ml1, the thickness of the epidermis decreased
by up to 1–3 cell layers and the basal cell layers disappeared
(Figure 5a). The nuclei of epidermal cells became
flattened and the cytoplasm showed eosinophilic individual
keratinization. These changes might imply accelerated term-
inal differentiation.
By contrast, samples treated with chPIP D22S peptide at a
concentration of 5–500mg ml1 gave epidermal cell layers
that were consistently 2–3 cell layers thick (Figure 5a). These
features were similar to control epidermal cell layers treated
with DW.
The thickness of the epidermis treated with hPIP peptide at a
concentration of 50 and 250mg ml1 significantly (Po0.05)
increased compared with control samples treated with chPIP
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Figure 5. Digestive effect of human prolactin-induced protein (hPIP) peptide on the stratum corneum and induction in the proliferation of epidermal
keratinocytes in the human three-dimensional (3-D) skin model observed by histopathology. (a) Human 3-D skin model treated with distilled water (DW), hPIP,
or control hPIP (chPIP). Concentration of hPIP or chPIP was as follows: 5, 25, 50, 250, or 500mg ml1. (b) The mean epidermal thickness from the human 3-D skin
treated with DW (n¼5) or hPIP peptide (50, 250 (n¼5), and 500mg ml 1 (n¼ 7)) and chPIP peptide (50, 250, and 500mg ml 1 (n¼ 3)). Repeated application of
hPIP peptide (50 or 250mg ml1) significantly (Po0.05) increased epidermal thickness compared with the controls treated with DW and also those samples treated
with chPIP (50 and 250mg ml 1). Mitotic figures (arrows) are seen (c: high magnification of panel a; treated with 50mg ml1 hPIP), and many epidermal cells were
positively stained with anti-proliferating cell nuclear antigen (PCNA) antibody (d: treated with hPIP 50mg ml1). Scale bar¼ 60mm. Arrowheads: epidermal
thickness; arrows: mitotic figure.
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D22S at the same concentration or those treated with DW
(Figure 5b). There appears to be no dose dependence to the
effect of hPIP on skin thickness.
DISCUSSION
As a prerequisite to this investigation, we immunohistochemi-
cally confirmed that PIP was ubiquitously found on the surface
of corneocytes from normal-appearing skin of all the healthy
individuals and patients with AD who participated in this
study. Using immunofluorescence analysis, PIP was also
found to localize at the surface of the stratum corneum, as
well as the eccrine ducts. Sequential tape stripping clarified
that the number of PIP–positive corneocytes decreased within
three or four layers in many of the healthy individuals.
However, numerous PIP–positive corneocytes were identified
in deeper layers of the stratum corneum in many of the AD
patients. The observed distribution of PIP suggests that this
molecule is exocrine (i.e., not an endogenous protease).
Furthermore, vertical distribution of PIP in layers of the stratum
corneum of AD patients showed that PIP was detected in
significantly deeper regions than in healthy individuals. This
might occur because of barrier dysfunction often seen in AD
(Cork et al., 2006). These findings also suggest that PIP
remains localized on the stratum corneum after the sweat
has evaporated. By dot-blot analysis, we determined the
concentration of PIP in sweat to be o0.4mg ml1 in four
adult cases and 4410mg ml1 in six adult cases. Indeed, the
concentration of PIP will increase because of the evaporation
of sweat. Moreover, we speculate that repeated rounds of
sweating results in the gradual accumulation of PIP on the
stratum corneum.
This study demonstrated that hPIP (residue 29–63)–treated
corneocytes from normal-appearing facial skin of infants with
eczema and also of healthy infants show deterioration of cell
shape and a diminution in the intensity of blue color
components of corneocytes after TB staining for corneocytes
obtained by the tape-stripping method. The deterioration of
corneocytes treated with hPIP was seen in 20 out of 27 infants
examined. We assume that these changes might reflect, at
least in part, a loss of some components from the corneocytes
as a result of the proteolytic activity of hPIP. However, TB
staining could not clarify which components had altered after
hPIP treatment. We then adopted another staining method
using the fluorescent lipophilic dye NR, which stains hydro-
phobic lipids found on the CE (Greenspan et al., 1985; Hirao
et al., 2001). NR staining revealed the decrease in
hydrophobic lipids from hPIP–treated corneocytes. Given that
NR–positive hydrophobic lipids are located on the CE, the
decrease in these lipids implies that hPIP might degrade
structural proteins in this layer of the skin. The loss of these
structural proteins might then induce a decrease in hydro-
phobic lipids, thereby reducing skin barrier function. In terms
of the damaging effect of hPIP on corneocytes, our findings
obtained by NR staining are significant (Po0.05) compared
with that of chPIP D22S. Moreover, the results obtained from
NR staining are consistent with those using the TB stain.
We then investigated the morphological effect of hPIP on
the fine structure of corneocytes using a human 3-D skin
model in conjunction with scanning electron microscopy.
Treatment with hPIP peptide induced a large number of
openings in almost all the keratinocytes observed. However,
treatment with chPIP D22S produced no such openings in the
keratinocytes. Thus, the morphological effect of hPIP on
corneocytes based on light microscopic observations after
staining with TB or NR was confirmed by electron micro-
scopic studies of a human 3-D skin model.
The aspartic peptidase domain of PIP is similar to that of
candidapepsin (Caputo et al., 2000). Secreted aspartic
proteinases from Candida are important virulence factors in
cutaneous and mucosal candidiasis (Bein et al., 2002).
Candidapepsin degrades host surface proteins and matrix
proteins such as mucin (Colina et al., 1996), fibronectin, and
laminin (Morschha¨user et al., 1997). In addition, candida-
pepsin has been shown to cleave human proteins such as
albumin, keratin, collagen, and hemoglobin (Gotoh et al.,
1995). Pepsin also has broad substrate specificity (Kageyama,
2006). PIP is an aspartyl proteinase that is known to cleave
fibronectin (Caputo et al., 2003). However, PIP might possess
broad substrate specificity and thereby degrade proteins
comprising the stratum corneum. Indeed, these previous
reports suggest that PIP might degrade different surface
proteins and matrix proteins in skin tissue.
We proposed that PIP might have an effect on the stratum
corneum. In terms of the role of protease activity in AD patho-
genesis, increases in serine protease levels in acute lesions
(Voegeli et al., 2009) and genetic variations of stratum corneum
chymotryptic enzyme (Vasilopoulos et al., 2004) have been
reported. House dust mites produce cysteine proteases and also
breakdown corneodesmosomes, which can lead to barrier
dysfunction (Deleuran et al., 1998). Staphylococcus aureus is
also a source of exogenous proteases, which could breakdown
the skin barrier (Miedzobrodzki et al., 2002). A genetic variant
of lymphoepithelial Kazal-type 5 serine protease inhibitor was
identified in both AD (Fortugno et al., 2012) and the Netherton
syndrome (Descargues et al., 2005). A decreased level of
functional lymphoepithelial Kazal-type 5 serine protease
inhibitor-1 inversely correlates with activation of endogenous
protease, the keratinocyte-derived kallikrein-related proteases 5,
6, 7, 13, and 14 in the stratum corneum, resulting in premature
breakdown of the corneodesmosomes and thinning of the
stratum corneum. PIP might interfere with the protease–
protease inhibitor equilibrium controlling desquamation
through a pathway akin to that involving lymphoepithelial
Kazal-type 5 serine protease inhibitor-1 or perhaps a different
evolutionary pathway.
It must be remembered that the destructive effect of hPIP on
corneocytes is an undesirable physiological consequence of
this protease. Specifically, PIP may have an important primary
role in the body as protease, but the aim of this study was to
analyze the secondary effect of this proteolytic activity on
human skin itself.
One of the most interesting findings of this study was that
hPIP peptide induced the proliferation of epidermal keratino-
cytes with chromatin-rich nuclei and mitotic changes in a
human 3-D skin model. By contrast, chPIP D22S produced no
such proliferation of epidermal keratinocytes.
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It is unclear whether PIP directly influences epidermal cell
proliferation or whether there is an indirect effect caused by
injury to the stratum corneum. Perturbation of epidermal
barrier function after mechanical damage caused by repeated
tape stripping correlates with initiation of the cytokine cascade
in human skin (Nickoloff and Naidu, 1994). Repeated tape
stripping induces marked epidermal proliferation in both
psoriasis patients and normal subjects (Hatta et al., 1997).
Similarly, epidermal proliferation after hPIP peptide
application might be induced by an indirect effect through
the degradation of the stratum corneum. We speculate that PIP
in the saliva might be an exacerbation factor for infantile
eczema of the perioral region. We further speculate that PIP
derived from saliva damages the skin barrier in a de novo
manner, potentially inducing epidermal proliferation without
any external antigenic factors.
We determined the concentration of PIP in saliva to be 2–
10mg ml1 in one infant with eczema and very much
410mg ml1 in five infants with eczema. PIP has the ability
to bind and inhibit the growth of several bacterial strains
(Schenkels et al., 1997). In addition, we speculate that high
concentrations of PIP persistently affect mucosal epithelium
within the oral cavity and induce continuous desquamation
of the mucosal epithelium. Basmaciogullari et al. (2000)
suggested that binding between PIP and CD4 blocks the
CD4–HLA-DR interaction. Therefore, a high concentration of
PIP in saliva might help suppress harmful immunoreaction
caused by external materials such as food.
The thickness of the epidermal cell layers in the human 3-D
skin model decreased after treatment with 500 mg ml 1 hPIP.
Thus, there appears to be no dose dependence to the effect of
PIP on skin thickness. The real reason for the decrease in skin
thickness is unclear. Fibronectin has been shown to inhibit the
terminal differentiation of human keratinocytes (Adams
and Watt, 1989). Therefore, it seems possible that hPIP at a
concentration of 500mg ml1 might cleave fibronectin and
then induce differentiation of basal keratinocytes.
A limitation of this study is that the levels of PIP in the
stratum corneum are uncertain, and hence the concentrations
of PIP tested in this manuscript could be higher compared
with the levels that typically occur in vivo.
This study clarified that the proteolytic effect of PIP is
evident not only in normal-appearing skin of infants with
eczema but also in normal skin of healthy infants. Therefore,
we cannot conclude that PIP is a causative agent specific
to AD.
Nonetheless, the most interesting clinical implication of this
study of the proteolytic effect of PIP on human skin might be
in relation to the predisposing sites of AD. Because the skin
barrier function of patients with AD is reduced compared with
that of normal subjects (Cork et al., 2006), PIP might penetrate
more efficiently into the skin of patients with AD than in
healthy individuals. Indeed, in this sequential tape-stripping
analysis, vertical distribution of PIP in stratum corneum layers
of AD patients was significantly deeper than in healthy
individuals. The predilection sites such as the antecubital
flexures or popliteal fossae and in the neck region (Rajka,
1989) correspond to regions of the body that tend to
accumulate sweat. Thus, we further speculate that the
frequent exacerbation of skin lesions in the predilection sites
of AD during the summer season might relate, at least in part,
to the aspartic peptidase activity of PIP in sweat.
MATERIALS AND METHODS
An adhesive technique for corneocyte immunohistology studies
This study was approved by ethics committee of Shige University of
Medical Science. Written informed consent was obtained before
conducting these experiments. To analyze the distribution of PIP on
the normal skin surface, we took corneocytes of stratum corneum
from normal-appearing skin in the antecubital area or the upper arm
using the tape-stripping method (Jenkins and Tresise, 1969). In all, 13
patients with AD (moderate to mild, mean age 32±10 years) and 9
healthy individuals (mean age 38±11 years) were included in the
surface distribution study. Nine patients with AD (moderate to mild,
mean age 31±14 years) and seven healthy individuals (mean age
43±14 years) were included in the sequential tape-stripping study to
analyze the distribution of PIP in deeper layers until the ninth layer of
the stratum corneum. Cellophane tape was used and we transferred
the corneocytes on the tape by putting them on a Mas-coated slide.
We removed the tape by soaking the slide in xylene for 12 hours.
Severity of AD in each patient was assessed using the eczema area
and the severity index and the Rajka and the Langeland score (Rajka
and Langeland, 1989).
Immunohistological staining for corneocytes obtained by tape
stripping and evaluation of the sequential tape-stripping study
Corneocytes obtained by the tape-stripping procedure were subjected
to immunohistological analyses using anti-human PIP antibodies. The
corneocytes were incubated with an mAb to human prolactin–
induced protein antibody (dilution 1:1000; Santa Cruz Biotechnology,
Santa Cruz, CA) at 4 1C overnight. The samples were then incubated
with peroxidase-labeled anti-rabbit or anti-mouse antibody (Histofine
Simplestain Max PO; Nichirei, Tokyo, Japan) for 30 min at room
temperature. Peroxidase activity was detected with 3,3-diaminoben-
zidine (Sigma-Aldrich, St Louis, MO). Sections were counterstained
with hematoxylin. To determine the vertical distribution of PIP in the
stratum corneum, the deepest PIP–positive layer was defined as
having five or more visual fields containing 10 or more PIP–positive
cells in each field (original magnification,  10) in 1 2 cm2 area.
Differences in the deepest PIP–positive layers between healthy
individuals and patients with AD were evaluated using the t-test.
Differences less than a false discovery rate of 0.05 were considered
significant.
Immunofluorescence study of human skin samples
We obtained six biopsy specimens from six adult patients with AD
(severe to moderate). The specimens were obtained from acute
lesions of AD and excluded chronic lesions, such as lichenified and
prurigo lesions. Scaly erythematous lesions were defined as acute
lesions. First, we prepared serial sections from the skin samples and
picked up sections that contained outlets of the eccrine duct. Biopsy
specimens were transferred to 10% buffered formalin and fixed
overnight. The fixed samples were embedded in paraffin and serially
sliced into 4mm sections. After dewaxing, sections were autoclaved at
120 1C for 1 minute in 10 mM sodium citrate buffer (pH 6  0). They
were then incubated for 2 hours at 37 1C, with primary antibodies to
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PIP (diluted 1:100; Santa Cruz Biotechnology), and then incubated for
1 hour at room temperature (RT) with Alexa Fluor 488 goat anti-
mouse IgG (Hþ L) antibody (Invitrogen, Japan, Tokyo). The slides
were then washed with 1 phosphate-buffered saline to remove
excess fluorescent dye and mounted with glycerol. Samples were
observed using a fluorescence microscope DMI4000B (Leica,
Wetzlar, Germany).
Measurement of PIP concentration in the sweat and saliva
Sweat, saliva, or PIP standard samples were heated to 95 1C
for 3 minutes in 2% SDS buffer (0.06 M Tris-HCl (pH 6  8), 5%
2-mercaptoethanol, 2% SDS, 5% sucrose) and washed with
the column (Pierce Detergent Removal Spin Columns; Thermo
Scientific, Rockford, IL). Samples were applied onto a nitrocellulose
membrane that had been pretreated with methanol for 1 minute and
DW for 5 minutes. The membrane was blocked for 1 hour at
room temperature with casein in TBS buffer (Blocker Casein in
TBS buffer; Thermo Scientific) and then washed three times for
10 minutes in TBST (TBS plus 0.1% Triton X-100). After washing,
the membrane was incubated with an mAb to human prolactin-
induced protein antibody (dilution 1:100; Santa Cruz Biotechnology)
at RT for 1 hour. The samples were then incubated with peroxidase-
labeled anti-rabbit or anti-mouse antibody (Histofine Simplestain Max
PO (M); Nichirei) for 1 hour at room temperature. Peroxidase activity
was detected with 3,3-diaminobenzidine (Histofine Simplestain DAB;
Nichirei).
The concentration of PIP in the sweat or saliva samples was
determined by comparison with the intensity of the PIP standard
samples. Sweat samples were obtained from five healthy individuals
(mean age 28±17 years) and five patients with AD (moderate to
mild, mean age 24±13 years). In addition, saliva samples were also
obtained from six infants with facial eczema (mean age 6.5±1.7
months). PIP standards of different concentrations (1mg ml 1,
0.2mg ml 1, 40 ng ml 1, and 8 ng ml 1) were visualized by
dot-blot analysis. Each sample from human was used at 10 times
dilution and visualized by dot-blot analysis. The concentration of PIP
in each sample was assessed by direct comparison between the
density of the corresponding blot with that of the standards of known
concentration.
Construction of human prolactin-induced protein gene peptide
The aspartic peptidase domain of human PIP has been determined to
comprise the following sequence: QDNTRKIIIKNFDIPKSVRPNDEV-
TAVLAVQTELK (Caputo et al., 2000). A synthetic peptide (hPIP)
corresponding to the aspartic peptidase domain of human PIP (29–63)
was used in this study. It has also been reported that the aspartic
peptidase activity of PIP is abolished upon introduction of the D22S
mutation (Caputo et al., 2000). Thus, as a negative control, we
synthesized a second peptide in which Asp22 was substituted with a
serine residue (chPIP D22S).
Application of hPIP peptide on the corneocytes of normal-
appearing facial skin from healthy infants and infants with
eczema, and staining with 0.01% neutral TB and 5lgml 1 NR
The corneocytes were obtained from 30 infants with eczema and 17
healthy infants by the tape-stripping method as described previously
(Jenkins and Tresise, 1969). The samples were treated with hPIP or
chPIP D22S (both at a concentration of 50mg ml 1) or as a negative
control with DW. In each case, the relevant peptide in 20ml of
solution was applied to the surface of corneocytes three times per day
for 2 consecutive days for TB staining and for 1 day for NR staining.
After treatment, the corneocytes were placed on a slide in xylene
overnight, which was then replaced with a graded series from 100%
ethanol to DW. In all, 27 samples (17 samples from infants with
eczema, mean age 3.4±1.4 years; 10 samples from healthy infants,
mean age 3.9±2.0 years) were prepared and stained with 0.01%
neutral TB. Twenty samples (13 samples from infants with eczema,
mean age 3.5±1.8 years and 7 samples from healthy infants, mean
age 2.2±0.94 years) were stained with 5mg ml 1 NR according to
the method of Greenspan et al. (1985) and observed by laser
microscopy Nikon C1si TE2000-E (Nikon, Tokyo, Japan).
Measurement of the hydrophobic lipid envelope with NR
fluorescent dye
Images of corneocytes treated with hPIP, chPIP D22S, or DW were
captured (original magnification,  40) and the intensity of NR
fluorescence measured with Nikon EZ-C1 (Tokyo, Japan). In the
measurements, we included more than 20 representative corneocytes
that were distributed as groups from a single-cell layer but excluded
isolated cells or double layers of cells. In each of the 20 samples,
within the demarcated area, we measured both the total intensity of
NR fluorescence and the square measure. Mean intensity of NR
fluorescence was calculated as the total intensity divided by square
measure. Furthermore, the mean NR fluorescent intensity of corneo-
cytes treated with chPIP D22S or hPIP was divided by that of the
DW–treated samples (i.e., values indicated as chPIP/DW and hPIP/
DW, respectively). The Student’s t-test was performed between chPIP/
DW and hPIP/DW.
Treatment with hPIP for the human 3-D skin model
The human 3-D skin model (TESTSKIN LSE-high) was purchased from
Toyobo (Osaka Japan) and cultivated using a standard protocol
(Sugibayashi et al., 2004). A 2-week-old culture of the skin model
with a diameter of 6 mm was used in this study. The investigation was
performed from days 14 to 19 at 37 1C in a CO2 incubator.
For the dose-dependent studies, we used six graded concentrations
(5, 25, 50, 100, 250, or 500mg ml 1) of both hPIP and chPIP D22S.
Both hPIP and chPIP D22S were diluted with DW. To ensure that our
PIP application study was reproducible, we conducted three inde-
pendent experiments using separate 3-D skin samples. In each case,
the relevant peptide in 20ml of solution was applied to the surface of
a 3-D skin model three times per day from days 1 to 5 (i.e., 15
applications in total). After treatment, the skin model samples were
fixed with 10% neutral formaldehyde.
In total, 55 sheets of human 3-D skin model were used in this
study. Five sheets of human 3-D skin model were subjected to
application with DW to act as negative controls. Twenty-five sheets of
human 3-D skin model were treated with 5, 25, 50, 100, or
250mg ml 1 hPIP (five sheets for each concentration). Seven sheets
of human 3-D skin model were treated with 500mg ml 1 hPIP.
Eighteen sheets of human 3-D skin model were treated with 5, 25, 50,
100, 250, or 500mg ml 1 chPIP D22S (three sheets for each
concentration). One sheet of skin model for each concentration of
chPIP D22S or hPIP along with the DW–negative control was
prepared for scanning electron microscopy. All of the sheets were
prepared for hematoxylin and eosin staining.
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Preparation of human 3-D skin samples for scanning electron
microscopy
Samples were fixed for 60 seconds in 2.5% glutaraldehyde (made up
in 50 mM phosphate buffer, pH 7.2) at room temperature (RT) and
then postfixed with 2% osmium tetroxide for 2.5 minutes at RT.
Samples were dehydrated in graded concentrations of ethanol
(60–100%) at RT and then substituted for isoamyl acetate and dried
using the critical point method. The specimens were coated with a
thin layer of gold. Finally, the specimens were observed with a JSM-
7505FA (Tokyo, Japan) scanning electron microscope.
Histological study of the human 3-D skin model treated with
hPIP peptide and measurement of epidermal thickness
The skin samples were processed into 4mm paraffin sections and
stained with hematoxylin and eosin or monoclonal mouse antiproli-
ferating cell nuclear antigen (Dako, Japan, Tokyo) as described
previously (Hall et al., 1990). The stained sections were then
examined by light microscopy.
Samples treated with hPIP peptide or chPIP D22S peptide (each at
50, 250 or 500mg ml 1) or DW were analyzed to determine
epidermal thickness. Specifically, epidermal thickness in the central
area of each sample was measured using hematoxylin- and eosin-
stained sections. Thickness was measured from the printed figures
using original magnification,  20.
Statistical analyses
Differences of epidermal thicknesses between controls and samples
treated with PIP peptides were evaluated using the t-test. Differences
less than a false discovery rate of 0.05 were considered significant.
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